[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620046":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"MACS group",null,"Mild autonomous cortisol-secreting adenoma group must at least have two elevated DST1mg (Cortisol \\> 50 nmol\u002FL or 1.8 µg\u002FdL) and a plasma ACTH level ≤ 20 pg\u002FmL",{"label":13,"type":10,"description":14,"interventionNames":10},"ANS group","Non-secreting adenoma must have a normal DST1mg (Cortisol ≤ 50 nmol\u002FL or 1.8 µg\u002FdL).",{"label":16,"type":10,"description":17,"interventionNames":10},"Control group","Control group is patients followed in the endocrinology department, free of any known adrenal pathology and with a DST1mg test \\\u003C 50nmol\u002FL and matched for age and sex to patients in groups 1 and 2.",[19,25],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Amandine FERRIERE","CONTACT","05 57 57 64 24","+33","amandine.ferriere@chu-bordeaux.fr",{"name":26,"role":21,"phone":27,"phoneExt":23,"email":28},"Julie Brossaud","05.57.82.15.01","julie.brossaud@chu-bordeaux.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hôpital du Haut-Lévêque","RECRUITING","Pessac","33604","France","FR",{"type":38,"coordinates":39},"Point",[40,41],-0.6324,44.80565,{"lat":41,"lon":40},[44],{"name":45,"role":21,"phone":22,"phoneExt":23,"email":24},"Amandine FERRIERE, Dr",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620046","new-clinical-decision-support-score-based-on-steroid-hormone-profiling-in-the-diagnosis-of-macs-100620046",false,"NCT07352527","New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of MACS","New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of Adrenal Adenomas With Moderate Autonomous Cortisol Secretion or MACS","MACSCORE","Inclusion Criteria:\n\nMACS and ANS group:\n\n* 18 years ≤ Age\n* Patient with one or more unilateral or bilateral adrenal nodules with spontaneous density \\\u003C 20 HU on CT and major axis ≥ 1 cm and without associated overt pathological hormonal secretion.\n* Patient with one or more uni or bilateral adrenal nodules not meeting the above density criteria but without malignancy criteria and stable in size on imaging after at least 6 months of follow-up and without associated overt pathological hormone secretion.\n* Written consent of the patient for his participation in the research (at the latest on the day of inclusion and before any examination required by the research).\n* Subject affiliated to or benefiting from a social security scheme.\n\nDiagnostic criteria (determined after blood sampling) for continuation of the study:\n\nMACS group:\n\n* At least two elevated DST1mg (Cortisol \\> 50 nmol\u002FL or 1.8 µg\u002FdL) AND\n* a plasma ACTH level ≤ 20 pg\u002FmL\n\nANS group:\n\n\\- Normal DST1mg (Cortisol ≤ 50 nmol\u002FL or 1.8 µg\u002FdL). The definition criteria for MACS and ANS were based on the latest recommandations of learned societies.\n\nControls group:\n\n* patients followed in the endocrinology department, free of any known adrenal pathology and with a DST1mg test \\\u003C 50nmol\u002FL.\n* matched for age and sex to patients in groups 1 and 2.\n\nNon -inclusion criteria:\n\n* Adrenal incidentaloma \\\u003C 1 cm in size.\n* Use of exogenous corticosteroids, whether systemic or local (inhaled, eye and ear drops, ophthalmic ointment, topical skin products, joint infiltration) in the 6 months prior to the trial, and drugs that interfere with the metabolism of dexamethasone.\n* Pregnant women.\n* Patients with any other life-threatening condition.\n* Patients with an intercurrent pathology at the time of blood sampling (fever, COVID infection, influenza....).\n* Urinary free cortisol (UFC) \\> at the limit of laboratory normality.\n* Patients under court protection.","ALL","18 Years",{"count":59,"type":60},291,"ESTIMATED","OBSERVATIONAL","The recent development of quantitative steroid metabolome profiling could be of interest for the positive diagnosis of mild autonomous cortisol-secreting adenoma (MACS). The aim of the study is to develop a predictive model of MACS status or non-secreting adenoma (NSA) based on a panel of 19 serum steroids and three clinico-biological parameters (body mass index or BMI, fasting glycaemia, blood pressure) and to estimate its performance for the diagnosis of MACS in a cohort of patients followed in the endocrinology department of Bordeaux University Hospital.",[64],"Endocrine Disease",[66,67,68,69],"Mild autonomous cortisol secreting adrenocortical adenoma","steroid hormone profiling","steroid metabolome","LC-MS\u002FMS","2026-01-13",{"date":72,"type":73},"2026-01-20","ACTUAL",{"date":75,"type":73},"2025-11-19",{"date":77,"type":60},"2027-05",{"name":5,"class":6},1]